AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that its partner AstraZeneca plc (NYSE: AZN) has submitted a New Drug Application (NDA) to the U.S. FDA for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) in patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) harboring MET overexpression or amplification whose disease progressed on or after treatment with an EGFR tyrosine kinase inhibitor (TKI) — a filing that would create the first targeted oral combination addressing MET‑driven resistance to Tagrisso in the U.S. market.

Regulatory Milestone

Drug Profiles & Mechanism of Action

• Orpathys (savolitinib): A potent, highly selective oral MET TKI with demonstrated clinical activity in advanced solid tumors. It blocks abnormal activation of the MET receptor tyrosine kinase signaling pathway caused by mutations (such as exon 14 skipping mutations or other point mutations), gene amplification, or protein overexpression.
• Tagrisso (osimertinib): An irreversible, third‑generation EGFR TKI with established clinical activity in NSCLC, including patients with central nervous system (CNS) metastases.
• Tagrisso Franchise: Approved as monotherapy in over 120 countries and regions worldwide — including the United States, the European Union, China, and Japan.
• Rationale for Combination: MET pathway activation — via overexpression or amplification — is a recognized on‑target resistance mechanism to EGFR TKIs in NSCLC. Dual blockade of MET and EGFR is designed to overcome this escape route with an all‑oral regimen.

Clinical & Scientific Context

• Resistance Landscape: A substantial share of NSCLC patients who progress on third‑generation EGFR TKIs such as Tagrisso exhibit MET‑pathway alterations, leaving chemotherapy as the current standard after progression — an oral targeted alternative would represent a meaningful shift in this setting.
• All‑Oral Convenience: Both components are orally administered small molecules, offering a chemotherapy‑free option with established CNS activity from Tagrisso.
• Biomarker‑Defined Population: The application targets a molecularly defined subgroup — MET overexpression or amplification — aligning with the FDA’s precision‑oncology framework for biomarker‑selected approvals.
• Supporting Data: Specific trials, efficacy endpoints, and safety results underpinning the NDA were not disclosed in the announcement.

Market Impact & Outlook

• HutchMed Royalty Stream: An FDA approval would extend the commercial reach of savolitinib beyond China into the world’s largest oncology market, strengthening HutchMed’s partner‑driven economics under its AstraZeneca collaboration.
• Tagrisso Lifecycle Extension: Pairing Tagrisso with savolitinib addresses post‑progression disease, potentially prolonging patients’ time on the franchise and defending its leadership position as competitors advance next‑line NSCLC regimens.
• Precision‑Oncology Positioning: A biomarker‑selected, all‑oral combination would differentiate AstraZeneca in the MET‑resistance niche, where antibody‑drug conjugates and amivantamab‑based strategies also compete.
• Review Risk: FDA evaluation, potential advisory committee review, and labeling decisions remain pending; the PDUFA date and any priority review designation were not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory review, approval timelines, and commercial expectations for the Orpathys–Tagrisso combination. Actual results may differ materially due to risks including FDA review outcomes, required additional data, competitive dynamics in NSCLC therapy, and commercialization execution.-Fineline Info & Tech